Skip to main content
 

Baseline leptin cutpoints predictive of metreleptin response by RIA and ELISA assays in patients with lipodystrophy

Friday, September 15, 2017 — Poster Session IV

1:00 p.m. – 2:30 p.m.
FAES Terrace
NIDDK
PHARM-4

Authors

  • N Malandrino
  • B Abel
  • S Auh
  • M Walter
  • M Startzell
  • E Cochran
  • P Gorden
  • RJ Brown

Abstract

Introduction: Lipodystrophies are rare disorders characterized by deficient adipose tissue and low endogenous leptin concentrations, leading to severe metabolic complications. Treatment with recombinant human leptin (metreleptin) significantly improves metabolic complications, especially in patients with pre-treatment endogenous leptin

Category: Molecular Pharmacology